ClinicalTrials.gg
Not yet recruitingNCT07558434Updated Apr 30, 2026

CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA

A Phase 2 interventional study of Cyclosporine (CsA) and thrombopoietin receptor agonist (TPO-RA) in Severe Aplastic Anemia (SAA) and Transfusion-dependent Non-severe Aplastic Anemia, sponsored by Peking Union Medical College Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Peking Union Medical College Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies testing cyclosporine in Anemia, Aplastic — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Anemia, Aplastic.

Planned enrollment
17th of 28
43 · median 49
Started
2026
with 1 other
Phase 2
22 of 28
4 open now
Registered
28th of 28
by date
Lead sponsor
6 of 28
Peking Union Medical College Hospital

Among the 28 studies testing cyclosporine in Anemia, Aplastic, this one is the 17th largest by planned enrollment, is one of 2 that started in 2026, is one of 22 in phase 2, and was the 28th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

5 of the 28 studies testing cyclosporine in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing cyclosporine in Anemia, Aplastic, or all of them as a file.
02

Study summary

This study aimed to explore the efficacy and safety of cyclosporine (CsA)

+eltrombopag (EPAG)/hetrombopag (HPAG)+romiplostim N01 in the treatment of newly-diagnosed transfusion-dependent aplastic anemia (TD-NSAA) and severe aplastic anemia (SAA)

03

Conditions studied

  • Severe Aplastic Anemia (SAA)
  • Transfusion-dependent Non-severe Aplastic Anemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old;
  2. Diagnosed with aplastic anemia (AA) through routine blood tests, bone marrow puncture, bone marrow , and exclusion tests, and determined as transfusion-dependent non-severe aplastic anemia (TD-NSAA) or severe aplastic anemia (SAA) according to the Camitta criteria; \< 30×10\^9/L;
  3. Had no HLA-matched donors or was not suitable for hematopoietic stem cell transplantation (HSCT);
  4. Not suitable for ATG, due to reasons such as age, complications, and the patient's own wishes;
  5. With baseline liver and kidney functions \<2 ;
  6. score ≤ 2;
  7. Signed the ;

Exclusion criteria

Exclusion Criteria:

  1. Had other primary or secondary bone marrow failure (BMF) diseases, such as Fanconi anemia, congenital keratinization disorder, etc.;
  2. With evidence of clonal hematological bone marrow diseases (MDS, AML) in cytogenetics;
  3. PNH clone ≥ 50%;
  4. Received before enrollment;
  5. Previously used treatments such as ATG, CsA, TPO receptor agonists (TPO-RAs);
  6. Allergic or intolerant to romiplostim N01, eltrombopag, hetrombopag, or CsA;
  7. Pregnant or lactating patients;
  8. Severe bleeding or infection that cannot be controlled by standard treatment;
  9. History of arterial or venous thrombosis;
  10. Complicated with malignant tumors;
  11. Participated in other clinical trials within 3 months;
  12. Patients considered not suitable to participate in this study by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (estimated)

Study arms

  • Experimental
    CsA+EPAG/HPAG+Romiplostim N01

    CsA 3-5mg/kg/d EPAG 50mg/d or HPAG 7.5mg/d Romiplostim N01 20µg/kg, subcutaneously, once a week

    Drug: Cyclosporine (CsA) · Drug: thrombopoietin receptor agonist (TPO-RA) · Drug: Romiplostim N01

Interventions

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    ORR=CRR+PRR

    Time frame: 6-month

Secondary outcomes

  1. ORR

    ORR=PRR+CRR

    Time frame: 3-month, 12-month

  2. red blood cell (RBC)/platelet (PLT) transfusion independent rate

    Proportion of patients who achieve red blood cell (RBC)/platelet (PLT) transfusion independence for 8 weeks or longer

    Time frame: 3-month, 6-month, 12-month

  3. AE rate

    proportion of patients with adverse events, according to CTCAE

    Time frame: through study completion, an average of 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2028, 32 months later.

Of 51 non-industry phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 111. This study's planned 32 months is below that.

Counting every sponsor, half of 59 studies reached it within 76 months; a quarter within 39 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
Apr 30, 2026
StartEst.
Apr 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07558434
Responsible party
Bing Han (Professor, Peking Union Medical College Hospital) — Principal investigator
First posted
Apr 30, 2026
Start date
Apr 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Apr 30, 2026

Study contacts

Bing Han
Contact
hanbing_li@sina.com.cn
+86 13601059938

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclosporine · Thrombopoietin Receptor Agonist · Romiplostim

Start the discussion